Vertex Pharmaceuticals Incorporated

NasdaqGS:VRTX Lagerbericht

Marktkapitalisierung: US$128.7b

Vertex Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Die Gewinne von Vertex Pharmaceuticals sind jährlich um durchschnittlich 1.4% gestiegen, während die Gewinne der Branche Biotechs jährlich um gewachsen um 19.1% gestiegen sind. Die Umsätze sind jährlich um gewachsen 17.6% gestiegen.

Wichtige Informationen

1.4%

Wachstumsrate der Gewinne

1.5%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie17.0%
Wachstumsrate der Einnahmen17.6%
Eigenkapitalrendite-3.1%
Netto-Marge-4.5%
Letzte Ertragsaktualisierung30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Nov 05

Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride

Oct 18

Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)

Oct 10

Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug

Sep 15

Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced

Sep 05

Vertex Stock: Came For CF Drugs, Staying For Gene Therapy

Aug 02

Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Jul 11
Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management

Jul 09

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jun 20
If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales

Jun 17

Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time

Jun 04

Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

May 09
Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 08
Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Apr 11

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Apr 05
Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15
Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22
We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07
Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25
Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Nov 13
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Oct 02
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03
We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Aufschlüsselung der Einnahmen und Ausgaben

Wie Vertex Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

NasdaqGS:VRTX Einnahmen, Ausgaben und Erträge (USD Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Sep 2410,626-4801,4190
30 Jun 2410,337-4901,3480
31 Mar 2410,1854,0191,2380
31 Dec 239,8693,6201,1370
30 Sep 239,6543,4701,0350
30 Jun 239,5053,3651,0180
31 Mar 239,2083,2609710
31 Dec 228,9313,3229450
30 Sep 228,7013,2739330
30 Jun 228,3503,1958840
31 Mar 227,9482,4518630
31 Dec 217,5742,3428400
30 Sep 217,1302,1767970
30 Jun 216,6841,9927830
31 Mar 216,4152,7627800
31 Dec 206,2062,7127710
30 Sep 205,9912,6917540
30 Jun 205,4032,0817290
31 Mar 204,8191,5116940
31 Dec 194,1631,1776590
30 Sep 193,6202,1446160
30 Jun 193,4542,2155940
31 Mar 193,2652,1555750
31 Dec 183,0482,0965580
30 Sep 182,8296475390
30 Jun 182,6234155230
31 Mar 182,4152265130
31 Dec 172,4892634960
30 Sep 172,2961964710
30 Jun 172,1312594570
31 Mar 172,0191774410
31 Dec 161,702-1124330
30 Sep 161,661-2194190
30 Jun 161,557-2754130
31 Mar 161,292-3993960
31 Dec 151,032-5563770
30 Sep 15759-6593590
30 Jun 15628-7343340
31 Mar 15600-7043170
31 Dec 14580-7383050
30 Sep 14787-5823000
30 Jun 14830-5303080
31 Mar 141,002-4283380
31 Dec 131,212-5043560

Qualität der Erträge: VRTX ist derzeit unrentabel.

Wachsende Gewinnspanne: VRTX ist derzeit unrentabel.


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: VRTX ist unrentabel, hat aber in den letzten 5 Jahren die Verluste mit einer Rate von 1.4% pro Jahr reduziert.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von VRTX verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: VRTX ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-2.3%) erschwert.


Eigenkapitalrendite

Hohe Eigenkapitalrendite: VRTX hat eine negative Eigenkapitalrendite (-3.07%), da es derzeit unrentabel ist.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren